2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Analyzing fundamentals for TSVT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TSVT Fundamentals page.
Watching at TSVT technicals we can see that long-term trend is bearish, the same as bearishmiddle-term trend, as well as bearishshort-term trend. More technicals details can be found on TSVT Technicals page.
An error has occurred. This application may no longer respond until reloaded.